Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 378

2.

[Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].

Mnie-Filali O, El Mansari M, Scarna H, Zimmer L, Sánchez C, Haddjeri N.

Encephale. 2007 Dec;33(6):965-72. doi: 10.1016/j.encep.2007.11.001. Epub 2007 Dec 11. Review. French.

PMID:
18789789
3.
4.

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.

Owens MJ, Knight DL, Nemeroff CB.

Biol Psychiatry. 2001 Sep 1;50(5):345-50.

PMID:
11543737
5.

Allosteric effects of R- and S-citalopram on the human 5-HT transporter: evidence for distinct high- and low-affinity binding sites.

Plenge P, Gether U, Rasmussen SG.

Eur J Pharmacol. 2007 Jul 12;567(1-2):1-9. Epub 2007 Apr 14.

PMID:
17499240
6.

Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.

Mansari ME, Wiborg O, Mnie-Filali O, Benturquia N, Sánchez C, Haddjeri N.

Int J Neuropsychopharmacol. 2007 Feb;10(1):31-40. Epub 2006 Feb 1.

PMID:
16448580
7.

An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant.

Zhong H, Hansen KB, Boyle NJ, Han K, Muske G, Huang X, Egebjerg J, Sánchez C.

Neurosci Lett. 2009 Oct 25;462(3):207-12. doi: 10.1016/j.neulet.2009.07.030. Epub 2009 Jul 16.

PMID:
19616061
8.

[Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine].

Owens JM, Knight DL, Nemeroff CB.

Encephale. 2002 Jul-Aug;28(4):350-5. French.

PMID:
12232544
9.

Characterization of an allosteric citalopram-binding site at the serotonin transporter.

Chen F, Larsen MB, Neubauer HA, Sánchez C, Plenge P, Wiborg O.

J Neurochem. 2005 Jan;92(1):21-8.

10.
11.

Molecular mechanism of citalopram and cocaine interactions with neurotransmitter transporters.

Ravna AW, Sylte I, Dahl SG.

J Pharmacol Exp Ther. 2003 Oct;307(1):34-41. Epub 2003 Aug 27.

12.

R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter.

Stórustovu Sí, Sánchez C, Pörzgen P, Brennum LT, Larsen AK, Pulis M, Ebert B.

Br J Pharmacol. 2004 May;142(1):172-80. Epub 2004 Mar 22.

13.

[Mechanisms of action of antidepressants: new data from Escitalopram].

Fabre V, Hamon M.

Encephale. 2003 May-Jun;29(3 Pt 1):259-65. French.

PMID:
12876551
14.

[Escitalopram and citalopram: the unexpected role of the R-enantiomer].

Jacquot C, David DJ, Gardier AM, Sánchez C.

Encephale. 2007 Mar-Apr;33(2):179-87. Review. French.

PMID:
17675913
15.

Dissection of an allosteric mechanism on the serotonin transporter: a cross-species study.

Neubauer HA, Hansen CG, Wiborg O.

Mol Pharmacol. 2006 Apr;69(4):1242-50. Epub 2006 Jan 24.

16.

Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors.

Hirano K, Kimura R, Sugimoto Y, Yamada J, Uchida S, Kato Y, Hashimoto H, Yamada S.

Br J Pharmacol. 2005 Mar;144(5):695-702.

18.

Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters.

Béïque JC, Lavoie N, de Montigny C, Debonnel G.

Eur J Pharmacol. 1998 May 15;349(1):129-32.

PMID:
9669506
20.

Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram.

Kasper S, Sacher J, Klein N, Mossaheb N, Attarbaschi-Steiner T, Lanzenberger R, Spindelegger C, Asenbaum S, Holik A, Dudczak R.

Int Clin Psychopharmacol. 2009 May;24(3):119-25. doi: 10.1097/YIC.0b013e32832a8ec8. Review.

PMID:
19367152

Supplemental Content

Support Center